Capricor Therapeutics enters June with its short position entrenched near a multi-month high, a cluster of insider sales fresh in the register, and the stock trading 12% below where it opened May.
The short setup has changed only at the margins since the May 26 note. Short interest dipped fractionally — from 10.94 million shares on May 27 to 10.91 million as of May 28 — and at 23.9% of the free float remains near the highest level of the past several months. The week-on-week decline of 2.3% confirms the modest easing trend flagged previously, but the one-month build of 19.3% shows how much ground was gained during the post-earnings selldown. The borrow market offers little drama. Cost to borrow runs at just 0.51%, barely changed on the week and down from 0.64% in late April — hardly the hallmarks of a squeeze setup. Availability has loosened further to 351%, up from 332% a week ago, meaning there are roughly 3.5 shares available to borrow for every one already lent out. The ORTEX short score has edged back to 68.9 from a peak of 73.7 in mid-May, still elevated but no longer building. The bear thesis is present; it is simply not accelerating.
The more noteworthy signal this week is insider activity. The CFO and General Counsel each sold 25,000 shares on May 1 — $792,000 apiece at around $31.70 — following a similar pattern of coordinated selling at month-end March, when the same two executives and a pair of directors together disposed of more than $5 million in stock. Across the 90-day window, net insider selling amounts to roughly $6.8 million. These are modest-sized transactions relative to the company's float, and the May 1 price of $31.70 is above the current $29.96, so the sellers had better timing than the holders who followed. None of the trades carries a high significance score, and the amounts are consistent with routine programmatic selling rather than a directional view — but the pattern is consistent and one-sided.
The institutional register provides a counterpoint. Several funds built positions meaningfully in Q1. Suvretta Capital added 2.9 million shares to reach 6.6% of the company. Tang Capital added 1.7 million shares and now holds 5.9%. State Street added 1.4 million shares. These are not passive-index flows; they represent deliberate accumulation at price levels close to current. Nippon Shinyaku, the Japanese pharma company and strategic partner, remains anchored at 8.5% with no reported change. That concentrated ownership picture — with the top five holders controlling roughly 30% of shares — creates a structural tension with the 23.9% short float: a meaningful proportion of the float is already committed on both sides.
Options are almost entirely neutral. The put/call ratio is running at 0.39, fractionally below its 20-day average of 0.41, and the z-score of -0.47 is well within normal range. At the 52-week extremes — a high of 3.16 and a low of 0.25 — the current reading is practically the quietest it has been all year. Whatever the options market thinks of CAPR, it is not saying it loudly. The valuation backdrop reinforces the pre-revenue stage of the story: the company carries negative P/E and EV/EBITDA, reflecting a pipeline asset rather than a cash-generating business. The next scheduled earnings event is August 6.
For now, the key watch-point is whether the short position — still nearly a quarter of the free float — begins a more decisive unwind, or whether a fresh catalyst reignites the bear build ahead of the Q3 print.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
